|
|
|
|
|
|
Technology |
Recombinant Rabbit Antibodies, Rabxody Technology- A Novel way to obtain antibodies:
Myxengo's Rabxody technology has been proven to overcome the many limitations of other antibody technologies.
It is highly diverse. Antibodies from rabbit tend to recognize a more diverse epitopes on a target which is an crucial factor in the area of disease target validation. This fact make it possible to discover specific antibodies accessing difficult disease targets. Current conventional technologies have limited ability to address these issues.
Therefore, Rabxody ttechnology can provides significant time and cost savings for the drug development and assay development process.
Furthermore recombinat rabbit antibody will be a trustable starting point for therapeutics antibody discovery process through humanization using highly diverse CDRs (Complementarity Determining Regions).
The Myxengo's proprietary Rabxody technology is a novel approach using single B cell cloning. Rabxody scrutinizes the large amount of DNA sequence information derived from B cells generated by the rabbit, to isolate very high affinity antibodies. The resultsed antibodies show high affinity with broad epitope recognition providing many benefits that have not been achieved using conventional technologies.
|
Highly diverse naive human scFv phage library- Express way to obtain leads for targets: |
Myxengo has produced large diverse libraries of antibodies which is over several tens of billion. Phage display enables Myxengo and our partners to identify highly potent therapeutic leads. The tremendous size of the library make it possible to rapidly identify drug candidates that bind with high specificity and affinity to targets of therapeutic interest.
We maintain kappa library and lambda library which make us to broadly target a wide range of therapeutic targets without bias.
The phage display process generally consists of:
1. Selecting binders having high affinity and specificity to a target from the phage display libraries
2. Producing and evaluating the selected binders to choose potential therapeutic leads
3. Converting the scFv into fully human IgG
4. Producing and evaluating the human IgG to choose final therapeutic leads
We believe that our proprietary phage library generating technology has several advantages over other technologies, including:
Diversity and abundance: Our phage display libraries can contain several tens of billion of potential binders.
Speed and cost effectiveness: We deliver fully human IgG as therapeutic candidates.
Flexible screening strategy: We have a flexible selection process allowing us to harness the power of phage disply.
Highly efficient affinity maturation: We are able to efficiently design and produce libraries based upon potential leads to further increase affinity. |
| |
| |
|
© Copyright 2010 Myxengo, Inc
|
|
